Health care advances are being tested at Wright State University and Premier Health to explore new treatments. The alliance is giving patients, physicians and industry new options in exploring what works — and what doesn’t. Find out what’s happening here.
One of OCTC’s partners, ClinicalRM, a member of the Global Emerging Pathogens Therapy/Treatment Consortium, begins clinical trials to study effective treatments and prevention of Ebola. Read more at: http://www.cleveland.com/healthfit/index.ssf/2014/11/new_ebola_treatment_study_effo.html
Cordgenics’ Presentation: ChemoID
August 18, 2014 10-11AM | Wearn 137, University Hospitals | Cleveland, OH
Learn more about ChemoID and the technology!
Cordgenics is a dynamic company which applies innovative approaches to develop personalized therapy for cancer. Our goal is to improve the survival rates of cancer patients and to identify novel anticancer drugs for pharmaceutical companies. Visit www.cordgenics.com for more information.
- ChemoID technology can assist in optimal chemotherapeutic selection
- Should this technology be adopted by the Case Comprehensive Cancer Center, Cordgenics’ services could be brought to University Hospitals and the Cleveland Clinic, promoting the medical industry and job growth in Ohio
- Cordgenics’ relationship with the Edwards Comprehensive Cancer Center at Huntington Hospital/Marshall University could be leveraged to be part of the OCTC’s future site expansion.
BIO 2014 Convention
June 23-26, 2014 | San Diego, CA
BIO Innovation Zone Company Snapshot: HemoShear LLC
Next week in San Diego at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science foundation (NSF) to host the first-ever BIO Invention Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech companies. To join us visit: convention.bio.org
OCTC and Oncology Working Group
On April 22, 2014, the Ohio Clinical Trials Collaborative (OCTC)—a group of nearly 70 clinicians, researchers, clinical trials coordinators, and compliance officers from eight medical centers and universities affiliated with the 3 Ohio Clinical and Translational Science Awards (CTSA) met for the second time during its semi-annual working meeting in Columbus.
The OCTC is a new statewide initiative under the umbrella of Ohio Governor John Kasich’s Medical Corridor project launched with the goals of creating jobs, attracting investors, improving health, and advancing medical science in Ohio. The OCTC is comprised of Ohio’s three (3) CTSA institutions and partners, and aims to utilize a reliant IRB mechanism, economies of scale, unique capacity, and existing statewide expertise to establish a robust clinical trials structure across Ohio. The OCTC is led by CWRU School of Medicine Dean Pamela Davis, MD, PhD, where James Chmiel, MD serves as the Director and Chief Executive.
As one of six OCTC working groups, the Oncology working group—led by Jill Barnholtz-Sloan, PhD and David Peereboom, MD—has set its initial focus on neuro-oncology, and is made up of neuro-oncologists, neurosurgeons, radiation oncologists and translational researchers from four Ohio academic medical centers. In addition to Drs. Barnholtz-Sloan and Peereboom, Gene Barnett, MD and Manmeet Ahluwalia, MD from Cleveland Clinic, Lisa Rogers, DO and Simon Lo, MD, from University Hospitals Case Medical Center, and Richard Curry, MD from University of Cincinnati Medical Center attended the all-day event and the Oncology working group meeting. Other physicians involved with the group are Andrew Sloan, MD from University Hospitals Case Medical Center, Ronald Warnick, MD and Chistopher McPherson, MD from University of Cincinnati Medical Center and Vinay Puduvalli, MD and J Bradley Elder, MD from Ohio State University Medical Center. The group discussed the current state of their prioritized multi-site therapeutic studies, ideas for new studies and expansion to pediatric neuro-oncology.
Ohio Clincial Trials Collaborative (OCTC) Video
Ohio Clincial Trials Collaborative: Your Access to Ohio’s Premier Medical Corridor
March 12, 2014 – Hinckley, Ohio
Clinical Research Management, Inc. (ClinicalRM)—a full-service Contract Research Organization (CRO) providing support for basic and applied research, clinical trials, and regulatory support—announced today it was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA). With this contract award ClinicalRM becomes part of a clinical studies network being established by BARDA to support development of vaccines, drugs, and diagnostics, known as medical countermeasures, needed to protect health and potentially save lives in public health emergencies. The network will provide clinical services in support of adequate and well-controlled phase 1through 4 clinical trials or trials during a public health emergency, and will support the evaluation of Chemical, Biological, Radiological, Nuclear, Pandemic Influenza and Emerging Infectious Disease medical countermeasures.
ClinicalRM is one of only 5 other companies to be awarded this contract. 100% of the total costs of the program will be financed with Federal money. It is a 2-year contract with three 1-years option BARDA may exercise. The total contract ceiling for 5-year program is $100 million.
Dr. David Hoover, ClinicalRM’s Program Director, stated “We look forward to working with BARDA to evaluate new treatments for medical conditions that could have devastating impacts on many people. New treatments are vitally important for improved management of infectious diseases and exposures to a broad range of toxic agents.
Dr. Alan Braverman, Vice President of Clinical Operations of ClinicalRM, noted that ClinicalRM with its longstanding tradition of creating meaningful partnerships with Government, industry and academia in infectious disease trials is honored to be selected and looks forward to being a key contributor to BARDA in achieving its mission.
Victoria Tifft, CEO of ClinicalRM, stated, “ClinicalRM is proud to engage in this critical work with BARDA. The award of this contract allows us to continue to build strong and meaningful partnerships with the Government, industry, and academia to combat a variety of potential national threats.”
Founded in 1994, ClinicalRM is a full-service CRO specializing in preclinical and Phase I-IV clinical research, clinical trial support, and product development for biologics, drugs, and devices. ClinicalRM prides itself on providing outstanding customer service and exceeding client expectations. For more information, please go to www.clinicalrm.com.
BARDA-Clinical Research Management, Inc
- A CRO based in Hinckley, OH
- NIH grant Phase I-IV clinical trials for infectious diseases.
- All ready are partners with CWRU and University of Cincinnati to conduct trials
- Awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) supporting development of vaccines, drugs, and diagnostics for medical countermeasures
- Clinical RM plans to leverage the OCTC for clinical trials pending approval from BARDA